NCT00100152终止1 期
A Phase I Study of a Gamma Secretase Inhibitor for Adult and Pediatric Patients With Relapsed or Refractory Acute T-Cell Lymphoblastic Leukemia and Lymphoma
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 50
研究概览
简要总结
A Notch signalling pathway inhibitor study in pediatric and adult patients with relapsed (worsening) or refractory (not responding to treatment) T-cell acute lymphoblastic leukemia/lymphoma (T-ALL).
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 12 Months 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have pathologically documented precursor T-cell acute lymphoblastic leukemia/lymphoma (T-ALL), relapsed or refractory to standard therapy, or not be a candidate for standard myelosuppressive chemotherapy due to age or comorbid disease.
- •Patient must have performance status <2 on the ECOG performance status for patients >16 years old; Lansky performance level >50 for patients 12 months to less than or equal to 16 years old.
- •Patient must have adequate renal and liver function as indicated by the laboratory values performed within 14 days of receiving the first dose of study drug.
- •Patient must have fully recovered from any chemotherapy and be greater than 2 weeks from radiotherapy, immunotherapy, or systemic steroid therapy with the exception of hydroxyurea, intrathecal therapy, or immunosuppressant therapy for chronic graft-versus-host disease prophylaxis following allogeneic bone marrow transplant.
- •Patient must be greater than 2 months following bone marrow or peripheral blood stem cell transplantation and off all immunosuppressant therapy (with the exception of patients taking immunosuppressant therapy for chronic graft-versus-host disease prophylaxis following allogeneic bone marrow transplant).
- •Men and women of reproductive potential must use an effective contraceptive method while enrolled in the study.
- •Patient or the patient's legal representative must be able to understand the study and give written informed consent.
排除标准
- •Patient has had treatment with any investigational therapy during the preceding 30 days.
- •Patient has uncontrolled congestive heart failure, angina, or had a myocardial infarction in the preceding 3 months.
- •Patient has known hypersensitivity to the components of study drug, its analogs, or to allopurinol.
- •Patient has active or uncontrolled infection.
- •Patient has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
- •Patient is pregnant or lactating.
- •Patient has any other severe concurrent disease which would make the patient inappropriate for entry into this study.
- •Patient is known to be HIV positive or who has an AIDS-related illness.
- •Patients with a "currently active" second malignancy, other than non-melanoma skin cancer should not be enrolled.
- •Patient has isolated CNS disease.
研究者
相似试验
终止
1 期
RO4929097 and Erlotinib Hydrochloride in Treating Patients With Stage IV or Recurrent Non-small Cell Lung CancerRecurrent Non-Small Cell Lung CarcinomaStage IV Non-Small Cell Lung CancerNCT01193881National Cancer Institute (NCI)16
已完成
1 期
Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic MelanomaRecurrent MelanomaStage IV Skin MelanomaNCT01196416National Cancer Institute (NCI)14
已完成
1 期
RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant GliomaAdult Anaplastic (Malignant) MeningiomaAdult Anaplastic AstrocytomaAdult Anaplastic EpendymomaAdult Brain Stem GliomaAdult Choroid Plexus NeoplasmAdult CraniopharyngiomaAdult Diffuse AstrocytomaAdult EpendymoblastomaAdult EpendymomaAdult Giant Cell GlioblastomaAdult GlioblastomaAdult GliosarcomaAdult Grade I MeningiomaAdult Grade II MeningiomaAdult MedulloblastomaAdult Mixed GliomaAdult Myxopapillary EpendymomaAdult OligodendrogliomaAdult Papillary MeningiomaAdult Pilocytic AstrocytomaAdult Pineal Gland AstrocytomaAdult PineoblastomaAdult PineocytomaAdult Primary Melanocytic Lesion of MeningesAdult Subependymal Giant Cell AstrocytomaAdult SubependymomaAdult Supratentorial Primitive Neuroectodermal TumorMalignant Adult Intracranial HemangiopericytomaAcoustic SchwannomaNCT01119599National Cancer Institute (NCI)22
已完成
2 期
Gamma Secretase Inhibitor RO4929097 in Previously Treated Metastatic Pancreas CancerAdenocarcinoma of the PancreasRecurrent Pancreatic CancerStage IV Pancreatic CancerNCT01232829National Cancer Institute (NCI)18
撤回
2 期
RO4929097 After Autologous Stem Cell Transplant in Treating Patients With Multiple MyelomaDS Stage I Plasma Cell MyelomaDS Stage II Plasma Cell MyelomaDS Stage III Plasma Cell MyelomaRefractory Plasma Cell MyelomaNCT01251172National Cancer Institute (NCI)